Impact BioMedical Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Impact BioMedical Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $2 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than almost all Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 810% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 89% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 36%
Sales fell 36% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-36% / -63%In 3 years sales changed by -36% while total assets changed by -63%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
2%Of every $100 the company owns, $2 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than almost all Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 83% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Impact BioMedical Inc. owes $0.16 for every $1 it owns. Impact BioMedical Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
0.3Investors pay $0.3 for every $1 of Impact BioMedical Inc.'s yearly profit, lower than 94% of Healthcare companies in United States.
P/B ratio
3.02The share price is 3.02 times Impact BioMedical Inc.'s book value per share, higher than 56% of Healthcare companies in United States.
Market cap
$32 MThe total market value of all of Impact BioMedical Inc.'s shares at today's price (share price × number of shares), smaller than 79% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$11 MWhat Impact BioMedical Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.26Net worth divided by the number of shares. The share price of $3.80 is 3.0 times this, which is the P/B above.
Return on equity (ROE)
23.5%Impact BioMedical Inc. earned 23.5% on its shareholders' money over the last year, higher than 92% of Healthcare companies in United States.
Owes vs Owns
0.16×Impact BioMedical Inc. owes $0.16 for every $1 it owns (low), lower than 78% of Healthcare companies in United States.
Dividend yield
NoneImpact BioMedical Inc. does not currently pay a dividend.
Profit growth
LossImpact BioMedical Inc. made a loss in each of the last two years.
Profit margin
-36993.8%Impact BioMedical Inc. lost $36994 for every $100 of revenue.
Interest cover
Not coveredImpact BioMedical Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Questions
What is Impact BioMedical Inc.'s P/E ratio?
Investors pay $0.3 for every $1 of Impact BioMedical Inc.'s yearly profit, lower than 94% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Impact BioMedical Inc.: $32 M ÷ $11 M (30 Jun 2026) = 3.0.
What is Impact BioMedical Inc.'s return on equity?
Impact BioMedical Inc. earned 23.5% on its shareholders' money over the last year, higher than 92% of Healthcare companies in United States.
How much does Impact BioMedical Inc. owe compared with what it owns?
Impact BioMedical Inc. owes $0.16 for every $1 it owns (low), lower than 78% of Healthcare companies in United States.
Does Impact BioMedical Inc. pay a dividend?
No. Impact BioMedical Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.